Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

@article{Winton2005VinorelbinePC,
  title={Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.},
  author={Timothy Winton and Robert B. Livingston and Diana. Johnson and James R. Rigas and Michael V. Johnston and Charles A. Butts and Yvon Cormier and Glenwood D Goss and Richard Inculet and Eric Valli{\`e}res and Willard A. Fry and Drew C. Bethune and Joseph Ayoub and Keyue Ding and Lesley K Seymour and Barbara Graham and Ming-Sound Tsao and David R Gandara and Kenneth A. Kesler and Todd L. Demmy and Frances A. Shepherd},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 25},
  pages={
          2589-97
        }
}
BACKGROUND We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer. METHODS We randomly assigned patients with completely resected stage IB or stage II non-small-cell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen… Expand
Improved compliance with adjuvant vinorelbine and cisplatin in non-small cell lung cancer.
TLDR
Compared to historical trials, adjuvant platinum-based chemotherapy for resected NSCLC is now accepted by patients and physicians with a high degree of compliance andMultivariate analysis showed no effect of age, gender, extent of surgery or ECOG status on compliance, need for treatment modification or toxicity. Expand
Adjuvant Carboplatin-based Chemotherapy in Resected Stage IIIA-N2 Non-small Cell Lung Cancer
  • W. Ou, Hai-bo Sun, +5 authors Si Yu Wang
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2010
TLDR
It is shown that adjuvant vinorelbine/paclitaxel plus carboplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected stage IIIA-N2 NSCLC. Expand
Feasibility of postoperative adjuvant chemotherapy using carboplatin plus S-1 in completely resected non-small cell lung cancer patients
TLDR
Adjuvant chemotherapy with carboplatin plus S-1 is safe and feasible, and two-year overall and disease-free survival rates were 96.3% and 53.3%, respectively. Expand
Post-operative treatment with cisplatin and vinorelbine in Chinese patients with non-small cell lung cancer: a clinical prospective analysis of 451 patients.
TLDR
Stratification analysis revealed that older age, histological type, pathological degree, but not the gender and smoking status, are independent factors affecting the length of survival in this population of Chinese patients with non-small cell lung cancer. Expand
Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
TLDR
Platinum-based adjuvant chemotherapy for surgically treated stage IB NSCLC might offer better survival than observation alone, and a large-scale randomized clinical trial is needed to validate these findings. Expand
Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non–Small-Cell Lung Cancer
  • G. Dy, P. Bogner, +10 authors N. Ramnath
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2014
TLDR
Patients with N2 clearance, less than or equal to 10% viable tumor in the resected specimen, and SLC19A1 rs3788189 TT genotype have favorable DFS outcomes. Expand
Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study.
TLDR
The combination of cisplatin/gemcitabine is a feasible and well-tolerated regimen in the adjuvant setting in patients with radically resected stage IB-III NSCLC and future trials should better define the best strategy in terms of efficacy, toxicity, and quality of life. Expand
Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer
TLDR
It is demonstrated that patients can benefit from the adjuvant chemotherapy in terms of OS and disease-free survival and uracil-tegafur seems to have no advantage in prolonging DFS, unless it is administered with platinum-based therapy. Expand
A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
BACKGROUND Adjuvant chemotherapy with vinorelbine plus cisplatin (NP) has been demonstrated to increase overall survival in patients with stage II or IIIA non-small cell lung cancer (NSCLC). AlthoughExpand
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
  • C. Pepe, B. Hasan, +7 authors F. Shepherd
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Despite elderly patients' receiving less chemotherapy, adjuvant vinorelbine and cisplatin improves survival in patients older than 65 years with acceptable toxicity, and adjuvant chemotherapy should not be withheld from elderly patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
TLDR
Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer and had a significantly higher survival rate than those assigned to observation. Expand
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
TLDR
Although survival was not improved, arm B offers a better palliation for advanced NSCLC patients than arm A, and arm B appears superior to arm A with regard to response rate, side effects, and QoL. Expand
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
TLDR
This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC and given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments. Expand
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
  • K. Kelly, J. Crowley, +10 authors D. Gandara
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
PC is equally efficacious as VC for the treatment of advanced non--small-cell lung cancer, and overall costs on the PC arm were higher than on the VC arm because of drug costs. Expand
Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
  • D. Waller, M. Peake, +5 authors S. Spiro
  • Medicine
  • European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • 2004
TLDR
This trial has failed to observe a survival benefit with adjuvant chemotherapy following complete resection of stage I-III NSCLC, but the hazard ratio and 95% confidence intervals are consistent with the previously reported meta-analysis and two large recently reported trials, which suggest a small survival Benefit with cisplatin-based chemotherapy. Expand
Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
TLDR
Patients randomized in Canada were more likely to fail to complete chemotherapy due to refusal of therapy than their American counterparts and differences between nations in the perception of the risks and benefits of adjuvant chemotherapy regimens, both between physicians and patients, should be investigated further. Expand
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
  • P. Bunn, K. Kelly
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1998
TLDR
Currently available chemotherapy given to non-small cell lung cancers patients with good performance status can improve survival to a similar extent as other solid tumors, such as small cell lung cancer and breast cancer. Expand
The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.
TLDR
Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC, however, women with non-squamous histology have increased survival when compared to men. Expand
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
  • P. Bonomi, K. Kim, +5 authors D. Johnson
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
Paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplarin as the reference regimen in the recently completed phase III trial of paclitaxels in advanced non-small-cell lung cancer. Expand
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
TLDR
Since the results have demonstrated that NVB-P yields a longer survival duration and a higher response rate than VDS-P or NVB alone, with acceptable toxicity, this combination should be considered a relevant regimen in advanced NSCLC. Expand
...
1
2
3
4
5
...